Extended genomic HLA typing identifies previously unrecognized mismatches in living kidney transplantation.
HLA mismatch
HLA typing
NGS
donor specific antibodies
epitope matching
kidney transplantation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
11
2022
accepted:
12
01
2023
entrez:
13
2
2023
pubmed:
14
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
Antibody mediated rejection (ABMR) is the most common cause of long-term allograft loss in kidney transplantation (KT). Therefore, a low human leukocyte antigen (HLA) mismatch (MM) load is favorable for KT outcomes. Hitherto, serological or low-resolution molecular HLA typing have been adapted in parallel. Here, we aimed to identify previously missed HLA mismatches and corresponding antibodies by high resolution HLA genotyping in a living-donor KT cohort. 103 donor/recipient pairs transplanted at the University of Leipzig Medical Center between 1998 and 2018 were re-typed using next generation sequencing (NGS) of the HLA loci -A, -B, -C, -DRB1, -DRB345, -DQA1, -DQB1, -DPA1, and -DPB1. Based on these data, we compiled HLA MM counts for each pair and comparatively evaluated genomic HLA-typing with pre-transplant obtained serological/low-resolution HLA (=one-field) typing results. NGS HLA typing (=two-field) data was further used for reclassification of By two-field HLA re-typing, we were able to identify additional MM in 64.1% (n=66) of cases for HLA loci -A, -B, -C, -DRB1 and -DQB1 that were not observed by one-field HLA typing. In patients with biopsy proven ABMR, two-field calculated MM count was significantly higher than by one-field HLA typing. For additional typed HLA loci -DRB345, -DQA1, -DPA1, and -DPB1 we observed 2, 26, 3, and 23 MM, respectively. In total, 37.3% (69/185) of Our results indicate that two-field HLA typing is feasible and provides significantly more sensitive HLA MM recognition in living-donor KT. Furthermore, accurate HLA typing plays an important role in graft management as it can improve discrimination between donor and non-donor HLA directed cellular and humoral alloreactivity in the long range. The inclusion of additional HLA loci against which antibodies can be readily detected, HLA-DRB345, -DQA1, -DQB1, -DPA1, and -DPB1, will allow a more precise virtual crossmatch and better prediction of potential DSA. Furthermore, in living KT, two-field HLA typing could contribute to the selection of the immunologically most suitable donors.
Identifiants
pubmed: 36776892
doi: 10.3389/fimmu.2023.1094862
pmc: PMC9911689
doi:
Substances chimiques
Histocompatibility Antigens Class I
0
Histocompatibility Antigens Class II
0
HLA-DQ beta-Chains
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1094862Informations de copyright
Copyright © 2023 Lehmann, Pehnke, Weimann, Bachmann, Dittrich, Petzold, Fürst, de Fallois, Landgraf, Henschler, Lindner, Halbritter, Doxiadis, Popp and Münch.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2022 Jun 20;13:844438
pubmed: 35799779
Hum Immunol. 2007 Mar;68(3):170-80
pubmed: 17349872
Hum Immunol. 2014 Apr;75(4):338-41
pubmed: 24486575
Front Immunol. 2022 Sep 29;13:924825
pubmed: 36248818
Transpl Int. 2004 Jan;17(1):22-30
pubmed: 12955350
Transplantation. 2012 Jul 27;94(2):172-7
pubmed: 22735711
Transpl Int. 2014 Jul;27(7):667-73
pubmed: 24629017
Clin J Am Soc Nephrol. 2019 Nov 7;14(11):1642-1650
pubmed: 31540931
Transpl Immunol. 2021 Apr;65:101287
pubmed: 32194154
HLA. 2021 Nov;98(5):431-447
pubmed: 34505410
Am J Transplant. 2011 Oct;11(10):2093-109
pubmed: 21883901
Ann Transplant. 2019 Jul 02;24:393-400
pubmed: 31263093
Lancet. 2019 Mar 2;393(10174):910-917
pubmed: 30773281
Pediatr Nephrol. 2020 Jan;35(1):83-94
pubmed: 31599339
Front Immunol. 2021 Jul 27;12:670956
pubmed: 34386000
Transplantation. 2006 May 15;81(9):1331-6
pubmed: 16699463
N Engl J Med. 1995 Aug 10;333(6):333-6
pubmed: 7609748
Am J Transplant. 2017 Dec;17(12):3076-3086
pubmed: 28613392
Kidney Int. 2020 Apr;97(4):778-785
pubmed: 32059998
Lancet. 2010 Oct 16;376(9749):1303-11
pubmed: 20727576
Transplantation. 1997 Nov 27;64(10):1473-5
pubmed: 9392314
HLA. 2020 Aug;96(2):141-162
pubmed: 32274854
Transplant Proc. 2018 Oct;50(8):2388-2391
pubmed: 30316363
Am J Transplant. 2018 May;18(5):1168-1176
pubmed: 29451350
Kidney Int. 2019 Jun;95(6):1471-1485
pubmed: 30955869
Transplantation. 2009 Jul 15;88(1):23-9
pubmed: 19584676
Hum Immunol. 2019 Dec;80(12):966-975
pubmed: 31604581
Transplantation. 2016 May;100(5):1094-102
pubmed: 26901078
Front Immunol. 2022 Sep 21;13:1005790
pubmed: 36211367
Kidney Int. 2018 Feb;93(2):491-500
pubmed: 28947279
J Am Soc Nephrol. 2020 Sep;31(9):2193-2204
pubmed: 32764139
Am J Transplant. 2012 Dec;12(12):3355-62
pubmed: 22959074
Am J Transplant. 2015 Apr;15(4):923-30
pubmed: 25778447
Transplantation. 2014 Mar 15;97(5):534-40
pubmed: 24595116
Transpl Immunol. 2015 Oct;33(2):51-7
pubmed: 26325207
Am J Transplant. 2019 Jul;19(7):1955-1963
pubmed: 30623581
Am J Transplant. 2020 Sep;20(9):2318-2331
pubmed: 32463180
Am J Transplant. 2013 Dec;13(12):3114-22
pubmed: 24164958
Clin Transplant. 2012 Jul-Aug;26(4):E428-37
pubmed: 22672477
Transpl Immunol. 2014 Jun;31(1):1-6
pubmed: 24769079
HLA. 2019 Sep;94(3):296-306
pubmed: 31237117
Clin J Am Soc Nephrol. 2016 May 6;11(5):875-83
pubmed: 27034399
HLA. 2020 Aug;96(2):163-178
pubmed: 32419382
Clin J Am Soc Nephrol. 2016 May 6;11(5):759-60
pubmed: 27034401
Am J Transplant. 2020 Dec;20(12):3277-3278
pubmed: 32484291
Hum Immunol. 2010 Sep;71(9):857-60
pubmed: 20510320
Am J Transplant. 2019 Nov;19(11):3100-3113
pubmed: 31062492